



Synthesis of FF-MAS from Lithocholic Acid

Anthony Murray, Frederik C. Grønvald, Jane K. Nielsen and Peter Faarup*

Novo Nordisk A/S, Novo Nordisk Park, 2760 Måløv, Denmark

Received 14 January 2000; accepted 9 March 2000

Abstract—An effective synthesis of 4,4 dimethyl-cholest-8,14,24-trien-3β-ol (FF-MAS) from lithocholic acid is described, utilising a double oxidation and regioselective Wittig reaction as key steps. © 2000 Elsevier Science Ltd. All rights reserved.

During ongoing research into compounds affecting meiosis it was our goal to find a suitable synthetic route for the synthesis of additional quantities of 4,4-dimethyl-cholest-8,14,24-trien-3 β -ol (1) (FF-MAS), a naturally occurring sterol isolated from human follicular fluid, and reported from our laboratories¹ to have a positive meiosis inducing effect on immature mouse oocytes.

Successful approaches to FF-MAS have been reported by Dolle et al.,² and more recently by Schroepfer et al.³ However, after initial attempts to follow the former route we found some of the synthetic steps problematic in our hands. As a result of our efforts in finding an alternative route, we report here the synthesis of FF-MAS from lithocholic acid.

Lithocholic acid was transformed in five steps⁴ to ester **2**, which was reduced with lithium aluminium hydride to afford the corresponding diol in 97% yield, and protected (92%) as the di-TBS ether **3**. To provide a suitable precursor to the required delta-8, delta-14 diene system, further unsaturation to give delta-7 was introduced via an allylic bromination/elimination sequence⁵ using 1,3-dibromo-5,5-dimethyl hydantoin followed by quinaldine, affording diene **4** in 48% yield. Exposure of

4 to HCl in refluxing methanol induced deprotection of both silyl groups and concomitant isomerisation to the required 8,14 diene system giving 5 in 55% yield (Scheme 1).

Attempts to selectively oxidise the primary side chain alcohol in 5 proved ineffective using either Swern, conventional chromium or ruthenium reagents, with irreproducible and generally low conversion to 7. In each case competitive dioxidation to keto aldehyde 6 usually predominated, and since the subsequent Wittig step on 7 to give FF-MAS was also low yielding, we decided therefore to utilise the 3-keto aldehyde 6 and investigate the feasability of a regioselective Wittig reaction. Diol 5 was smoothly oxidised with TPAP/NMO⁶ in 70% yield to 6, and the homologation step proceeded in 50% yield to afford the complete sterol side chain. A final reduction at C-3 with lithium aluminium hydride afforded FF-MAS (1) in 72% yield⁷ (Scheme 1), which was identical to that isolated from the natural source. ^{1a}

In summary, we have developed an effective synthesis of FF-MAS from lithocholic acid, which allows access to gram quantities of the endogenous ligand. Further synthesis of meiosis activating sterols⁸ analogous to FF-MAS will be reported in due course.

0960-894X/00/\$ - see front matter © 2000 Elsevier Science Ltd. All rights reserved. PII: \$0960-894X(00)00160-8

^{*}Corresponding author. Tel.: +44-444-34806; fax: +44-444-34547; e-mail: pef@novo.dk

Scheme 1. Reagents and conditions: (a) LiAlH₄, THF (97%); (b) TBSCl, imidazole, DMF (92%); (c) (i) dimethyl bromohydantoin, hexane/benzene (48%); (ii) quinaldine/o-xylene (80%); (d) HCl, EtOH, benzene (55%); (e) TPAP, NMO, DCM (70%); (f) Me₂CHPPh₃I, BuLi, THF (50%); (g) LiAlH₄, THF (72%); (h) (PPh₃)₃RuCl₂, benzene (30-60%); (j) as for f (19%).

Acknowledgements

We thank Jens Breinholdt for NMR and HLPC assistance.

References and Notes

1. (a) Byskov, A. G.; Andersen, C. Y.; Nordholm, L.; Thøgersen, H.; Guoliang, X.; Wassman, O.; Andersen, J. V.; Guddal, E.; Roed, T. *Nature* **1995**, *374*, 559. (b) Grøndal, C.; Ottesen, J. L.; Lessl, M.; Faarup P.; Murray, A.; Grønvald, F, C.; Hegle-Hartung, C.; Ahnfelt-Rønne, I. *Biology of Reproduction* **1998**, *58*, 1297.

2. (a) Dolle, R. E.; Schmidt, S. J.; Erhard, K. F.; Kruse, L. I. *J. Am. Chem. Soc.* **1989**, *111*, 278. (b) Dolle, R. E; Kruse, L. I *J. Org. Chem.* **1986**, *51*, 4047.

3. (a) Ruan, B.; Wilson, W. K.; Schroepfer, G. J. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 233. (b) Ruan, B.; Watanabe, S.; Eppig, J. J.; Kwoh, C; Dzidic, N; Pang, J; Wilson, W. K.; Schroepfer, G. J. *Lipid Research* **1998**, *39*, 2005.

4. Aranda, G.; Fetizon, M.; Tayeb, N. Tetrahedron 1987, 43, 4147.

Prelle, A.; Winterfeldt, E. *Heterocycles* 1989, 28, 333.
Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. *Synthesis* 1994, 641.

7. Physical data: **6**, mp 96.5–97 °C. ¹H NMR (CDCl₃, 300 MHz); 9.79 (1H, s, CHO), 5.40 (1H, s, H-15), 1.10 and 1.04 (3H each, s, CH₃-4α and 18), 0.93 (3H, d, J=6 Hz, CH₃-20), 0.82 (6H, s, CH₃-4β and 19), 2.6.8 (m, remaining H). ¹³C NMR (CDCl₃, 75 MHz); 218.1 (C-3), 203.3 (C-24), 151.1 (C-8), 140.3 (C-9), 126.2 (C-14), 118.2 (C-15), 57.3, 51.3, 47.6, 45.5, 41.3, 38.0, 37.4, 36.7, 36.2, 34.8, 34.0, 28.2, 28.1, 27.2, 21.8, 21.3, 20.5, 19.9, 19.0, 16.1. Anal. calcd for C₂₆H₃₈O₂: C, 81.62; H, 10.01. Found: C, 81.85; H, 10.56. MS: calcd for C₂₆H₃₈O₂: 382.6. Found: 382.3.

1, mp 126.5.5°C. ¹H NMR (CDCl₃, 300 MHz); 5.35 (1H, s, H-15), 5.10 (1H, t, J=6 Hz, H-24), 3.22 (1H, dd, J=12, 5 Hz, H-3), 1.69 and 1.61 (3H each, s, CH₃-26 and 27), 1.04 and 1.02 (3H each, s, CH₃-4α and 18), 0.94 (3H, d, J=6 Hz, CH₃-20), 0.83 and 0.80 (3H each, s, CH₃-4β and 19), 2.4.8 (m, remaining H). ¹³C NMR (CDCl₃, 75 MHz) 151.4 (C-8), 142.1(C-9), 131.3 (C-25), 125.5 (C-14), 123.2 (C-24), 117.7 (C-15), 79.0 (C-3). Anal. calcd for C₂₉H₄₆O: C, 84.81; H, 11.29. Found: C, 84.72; H, 11.75. MS: calcd for C₂₉H₄₆O: 410.7. Found: 411. 8. For an initial publication see Wenckens, M.; Grønvald, F.; Bondo Hansen, J. *Acta Chem. Scand.* **1998**, 52, 503.